Certara to Divest Regulatory and Medical Writing Business

Certara ( (CERT) ) has shared an announcement.

On April 21–22, 2026, Certara entered a definitive agreement to sell its global Regulatory and Medical Writing business, including related subsidiaries and assets, to Veristat for up to $135 million in cash, comprising $100 million upfront and up to $35 million in earn‑outs. The deal, expected to close in the second quarter of 2026 subject to customary conditions and possible escrow of up to $15 million, involves a unit that generated $50 million in 2025 revenue, $17 million in adjusted EBITDA and employs about 220 staff.

Management said the divestiture will sharpen Certara’s focus on its core model‑informed drug development and Clinical Intelligence solutions and support accelerated investment in its integrated MIDD platform and product innovation. The move signals a strategic pivot away from services‑heavy regulatory writing work toward higher‑margin, AI‑integrated software and analytics, with the company planning to update its 2026 guidance once the transaction closes, an event that could reshape its growth profile and capital allocation priorities for customers and shareholders.

The most recent analyst rating on (CERT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Certara stock, see the CERT Stock Forecast page.

Spark’s Take on CERT Stock

According to Spark, TipRanks’ AI Analyst, CERT is a Neutral.

The score is supported primarily by strong cash generation and a low-risk balance sheet, which reduce downside risk. Offsetting this are weak technical trends, a high P/E valuation, and mixed earnings-call signals including conservative 2026 growth guidance and disclosed execution challenges.

To see Spark’s full report on CERT stock, click here.

More about Certara

Certara, Inc., listed on Nasdaq as CERT, is a global leader in model‑informed drug development that accelerates medicines using biosimulation software, technology and services. The company serves more than 2,600 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries, focusing on data‑driven solutions across the drug discovery and development lifecycle.

Certara’s portfolio centers on model‑informed drug development and Clinical Intelligence platforms, which are increasingly being integrated with AI‑driven modeling and simulation. By concentrating resources on these higher‑growth, technology‑intensive areas, the company aims to deepen its role in shaping how pharmaceutical R&D is designed, analyzed and brought through regulatory review worldwide.

Average Trading Volume: 3,662,780

Technical Sentiment Signal: Sell

Current Market Cap: $949.1M

For detailed information about CERT stock, go to TipRanks’ Stock Analysis page.